A CD4-CDR3 Peptide Analog Inhibits Both Primary and Secondary Autoreactive CD4+ T Cell Responses in Experimental Allergic Encephalomyelitis

Journal of Immunology

Volumn 157, Issue 8, 1996, Pages 3706-3715

  Marini, Joseph C ^a   Jameson, Bradford A ^a,c   Lublin, Fred D ^b   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Ares Advanced Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; OLIGOPEPTIDE; REVERSE D AMINO ACID MOUSE PROLINE GLYCINE PROLINE PEPTIDE; REVERSE D AMINO ACID MOUSE PROLINE-GLYCINE-PROLINE PEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; AUTOIMMUNITY; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; FEMALE; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; LYMPH NODE; MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD4; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-4; LYMPH NODES; MICE; OLIGOPEPTIDES;

EID: 0030587824     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Alvord, E. C. 1986. Experimental allergic encephalomyelitis: a useful model for multiple sclerosis. In Proceedings of Clinical Biology Research. E. C. Alvord, M. W. Kies, A. J. Suckling, eds. Alan R. Liss, New York, p. 46.
2. Ben-Nun, A., H. Wekerle, and I. R. Cohen. 1981. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11:195.
3. - T lymphocytes. J. Immunol. 127:1420.
4. Traugott, U., E. L. Reinherz, and C. S. Raine. 1983. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 219:308.
5. Hafler, D. A., and H. L. Weiner. 1987. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol. Rev. 100:307.
6. Brostoff, S. W., and D. W. Mason. 1984. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J. Immunol. 133:1938.
7. Waldor, M. K., S. Sriram, R. Hardy, L. A. Herzenberg, L. Lanier, M. Lim, and L. Steinman. 1985. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 227:415.
8. Sriram, S., and C. A. Roberts. 1986. Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies. J. Immunol. 136:4464.
9. O'Neill, J. K., D. Baker, A. N. Davison, S. J. Allen, C. Butter, H. Waldmann, and J. L. Turk. 1993. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J. Neuroimmunol. 45:1.
10. Weyand, C. M., J. Goronzy, K. Swarztrauber, and C. G. Fathman. 1989. Immunosuppression by anti-CD4 treatment in vivo: persistence of secondary antiviral immune responses. Transplantation 47:1034.
11. + cells during the sensitization but not effector phase of accelerated rejection of rat cardiac allografts. Transplant. Proc. 22:2115.
12. Chace, J. H., J. S. Cowdery, and E. H. Field. 1994. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J. Immunol. 152:405.
13. Jameson, B. A., J. M. McDonnell, J. C. Marini, and R. Korngold. 1994. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368:744.
14. McDonnell, J. M., K. J. Blank, P. E. Rao, and B. A. Jameson. 1992. Direct involvement of the CDR3-like domain of CD4 in T helper cell activation. J. Immunol. 149:1626.
15. Townsend, R. M., C. Briggs, J. C. Marini, G. F. Murphy, and R. Korngold. 1996. Inhibitory effect of a CD4-CDR3 peptide analog on graft-vs-host disease across a MHC-haploidentical barrier. Blood 88:1996.
16. Korngold, R., A. Feldman, L. B. Rorke, F. D. Lublin, and P. C. Doherty. 1986. Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Immunogenetics 24:309.
17. Kuchroo, V. K., R. A. Sobel, J. C. Laning, C. A. Martin, E. Greenfield, M. E. Dorf, and M. B. Lees. 1992. Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein: fine specificity and T cell receptor Vβ usage. J. Immunol. 148:3776.
18. Knobler, R. L., F. D. Lublin, D. S. Linthicum, M. Cohn, R. D. Melvold, H. L. Lipton, B. A. Taylor, and W. G. Beamer. 1988. Genetic regulation of susceptibility and severity of demyelination. Ann. NY Acad. Sci. 540:735.
19. Brostoff, S. W., and T. M. White. 1986. Treatment of clinical experimental allergic encephalomyelitis in the rat with monoclonal antibodies. J. Neuroimmunol. 13:233.
20. + cells. J. Immunol. 140:713.
21. + cells. J. Immunol. 137:3414.
22. Hutchings, P., L. O'Reilly, N. M. Parish, H. Waldmann, and A. Cooke. 1992. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to β cells in NOD mice. Eur. J. Immunol. 22:1913.
23. Goronzy, J., C. M. Weyand, and C. G. Fathman. 1986. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. J. Exp. Med. 164:911.
24. Winter, G., and W. J. Harris. 1993. Humanized antibodies. Immunol. Today 14:243.
25. Roguska, M. A., J. T. Pedersen, C. A. Keddy, A. H. Henry, S. J. Searle, J. M. Lambert, V. S. Goldmacher, W. A. Blattler, A. R. Rees, and B. C. Guild. 1994. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 91:969.
26. Steinman, L., J. T. Rosenbaum, S. Sriram, and H. O. McDevitt. 1981. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. USA 78:7111.
27. Acha-Orbea, H., D. J. Mitchell, L. Timmermann, D. C. Wraith, G. S. Tausch, M. K. Waldor, S. S. Zamvil, H. O. McDevitt, and L. Steinman. 1988. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54:263.
28. Hafler, D. A., J. Ritz, S. F. Schlossman, and H. L. Weiner. 1988. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis: immunosuppressive effects and human anti-mouse responses. J. Immunol. 141:131.
29. Racadot, E., L. Rumbach, M. Bataillard, J. Galmiche, J-L. Henlin, M. Truttmann, P. Herve, and J. Wijdenes. 1993. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody: a preliminary report on B-F5 in 21 patients. J. Autoimmun. 6:771.
30. Lindsey, J. W., S. Hodgkinson, R. Mehta, D. Mitchell, D. Enzmann, and L. Steinman. 1994. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36:183.
31. Wraith, D. C., D. E. Smilek, D. J. Mitchell, L. Steinman, and H. O. McDevitt. 1989. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 59:247.
32. U J. Immunol. 148:3049.
33. Tisch, R., and H. O. McDevitt. 1994. Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity? Proc. Natl. Acad. Sci. USA 91:437.
34. Nicholson, L. B., J. M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397.
35. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381.
36. + donor T cells fail to induce experimental acute graft-vs-host disease. J. Immunol. 155:585.
37. Kuchroo, V. K., C. A. Martin, J. M. Greer, S-T. Ju, R. A. Sobel, and M. E. Dorf. 1993. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 151:4371.
38. Khoury, S. J., W. W. Hancock, and H. L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential up-regulation of transforming growth factor β, interleukin 4 and prostaglandin E expression in the brain. J. Exp. Med. 176:1355.
39. Miller, A., A. Alsabagh, L. M. B. Santos, M. Prabhu-Das, and H. L. Weiner. 1993. Epitopes of myelin basic protein (MBP) that trigger TGF-β release following oral tolerization to MBP are different from encephalitogenic epitopes. J. Immunol. 151:7307.
40. Newell, M. K., L. J. Haughn, C. Maroun, and M. H. Julius. 1990. Death of mature T cells by separate ligation of CD4 and T-cell receptor for antigen. Nature 347:286.
41. Saizawa, K., J. Rojo, and C. A. Janeway, Jr. 1987. Evidence for a physical association of CD4 and the CD3:α:β T-cell receptor. Nature 328:260.
42. Rivas, A., S. Takada, J. Koide, G. Sonderstrup-McDevitt, and E. G. Engleman. 1988. CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells. J. Immunol. 140:2912.
43. Janeway, C. A. 1992. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu. Rev. Immunol. 10:645.
44. Mittler, R. S., B. M. Rankin, and P. A. Kiener. 1991. Physical associations between CD45 and CD4 or CD8 occur as late activation events in antigen receptor-stimulated human T cells. J. Immunol. 147:3434.
45. lck with CD4 inhibits the induction of growth through the αβ T cell receptor. Nature 358:323.
46. Bank, I., and L. Chess. 1985. Perturbation of the T4 molecule transmits a negative signal to T cells. J. Exp. Med. 162:1294.
47. lck association. J. Exp. Med. 179:1973.
48. Langedijk, J. P. M., W. C. Puijk, W. P. Van Hoorn, and R. H. Meloen. 1993. Location of CD4 dimerization site explains critical role of CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC. J. Biol. Chem. 268:16875.
49. Ramsdell, F., and B. J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistence of antigen. Science 257:1130.
50. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
51. + T cell function. J. Biol. Chem. In press.